ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
A Charge-Adhesive Targeted DNA Gel Bandage for the Precision Treatment of Inflammatory Bowel Disease.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics.Signal transduction and targeted therapy · 2026Review
- Bioresponsive PDA-GelMA hydrogel microspheres coordinate redox-immune homeostasis via controlled rhMUC13 delivery for radiation-induced intestinal injury.Materials today. Bio · 2026Article
- A Charge-Adhesive Targeted DNA Gel Bandage for the Precision Treatment of Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The exacerbation and recurrence of inflammatory bowel disease (IBD) are closely related to the overactivation of the immune system and the destruction of the intestinal mucosa. Current small-molecule and biopharmaceutical therapies for IBD are often limited by off-target effects, low bioavailability, and poor treatment outcomes, leading to systemic side effects and severe complications. To address these challenges, DNA gel bandage (DNAgb) designed to block immune cell homing and inhibit inflammatory responses are proposed. DNAgb is a negatively charged "sticky excipient" formed by a rolling circle amplification production hydrogel and an integrin α4 aptamer (ApITGA4) -guided tetrahedral DNA nanostructure. This unique design enables dual-specific localization to inflamed mucosa through electrostatic interactions and ApITGA4-mediated affinity targeting. Our studies have demonstrated that DNAgb exhibits precise targeting, superior stability, and robust anti-inflammatory efficacy. It effectively inhibits activation of the NF-κB signaling pathway, decreases the secretion of inflammatory factors and reshapes the immune microenvironment. Transcriptome analysis further reveals the underlying mechanism of DNAgb in IBD therapy, highlighting its role in inflammation repression. Therefore, DNAgb provides a promising strategy for local therapeutic agents that effectively inhibit the inflammatory response and provides a new and effective choice for the treatment of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.